As a National Cancer Institute-designated comprehensive cancer center, City of Hope’s urology and urologic oncology program is uniquely positioned to provide personalized and comprehensive treatment plans, along with access to groundbreaking clinical trials.
For more than a decade, U.S. News & World Report has named City of Hope one of the top cancer hospitals in America, as well as named a high performing hospital in urology. Our world-class experts offer urology and urologic cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies.
NCT04223856: Yung Lyou, M.D., Ph.D.,
is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer.
Patient Enrollment Qualifications
18 years of age or older
Histologically documented, unresectable locally advanced or metastatic urothelial carcinoma
Recurrent Locally Advanced or Metastatic Urothelial Cancer
NCT03237780: Yung Lyou, M.D., Ph.D.,
is actively recruiting patients for a Phase 2 study on the benefits of atezolizumab, with or without eribulin mesylate, in treating patients with urothelial cancer that has come back, or spread to nearby tissues and lymph nodes, or other places in the body.
18 years of age or older
Histologically confirmed diagnosis of advanced/unresectable and/or metastatic transitional cell urothelial cancer of the renal pelvis, ureter, urinary bladder or urethra
Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT04197986: Sumanta Pal, M.D.,
is actively recruiting patients for a Phase 3 trial studying the benefits of an oral targeted therapy for the adjuvant treatment of patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations that is considered high risk for recurrence with surgery alone.
18 years of age or older
A histologically or cytologically confirmed, invasive urothelial carcinoma with susceptible FGFR3 alterations within 120 days following nephroureterectomy, distal ureterectomy or cystectomy
Patients must have no evidence of metastatic disease based on screening computed tomography or magnetic resonance imaging.
